In these studies, patients experienced elevated rates of adverse reactions, including weight loss, decreased BMI, decreased appetite, insomnia, infections (upper respiratory and nasopharyngitis), irritability, and affect lability
This is actually beneficial for timing flexibility, because it means your body does not respond to each dose as if it is the first time
Materials and Methods: The patients were randomly assigned to receive subcutaneous tirzepatide once a week at doses of 1, 5, 10, or 15 mg, dulaglutide at a dose of 1.5 mg, or a placebo
Substrate profiling of glutathione S-transferase with engineered enzymes and matched glutathione analogues
Wierenga CE, Dev SI, Shin DD, Clark LR, Bangen KJ, Jak AJ, et al
The FDA has approved Wegovy for adolescents 12 and older with obesity, but that path runs through in-person pediatric care